Completed PHASE2 INTERVENTIONAL 1-arm NCT00154349

Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

Sponsor: Novartis Pharmaceuticals

Conditions Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

Updated 6 times since 2017 Last updated: Feb 21, 2017 Started: Oct 31, 2003 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00154349, this PHASE2 trial focuses on Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Mar 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Mar 2017 [monthly]

Completed PHASE2

First recorded

Oct 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.